CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 74 enrolled
Drug / intervention
Brinzolamide 1% and timolol 0.5% fixed combination eye dropsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01484951
NCT01484951Phase 4Completed
CompareCT.gov

Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan

Alcon Research·interventional·Posted Dec 5, 2011·Updated May 1, 2013

In Brief

A Phase 4 clinical trial evaluating Brinzolamide 1% and timolol 0.5% fixed combination eye drops for Glaucoma. Completed, enrolled 74 participants across 1 site.

Detailed Summary

The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2011
Enrollment StartMay 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.6 years ago

Interventions

Brinzolamide 1% and timolol 0.5% fixed combination eye dropsdrug